Orthocell Ltd
ASX:OCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BSEL Infrastructure Realty Ltd
BSE:532123
|
IN |
|
Ningbo Sanxing Medical Electric Co Ltd
SSE:601567
|
CN |
Orthocell Ltd
EPS (Diluted)
Orthocell Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orthocell Ltd
ASX:OCC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Mesoblast Ltd
ASX:MSB
|
EPS (Diluted)
$0
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
EPS (Diluted)
$2
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
55%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Orthocell Ltd
Glance View
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is engaged in the development and commercialization of cell therapies and biological medical devices. The firm offers two main products, including CelGro and Ortho-ATI. CelGro is a naturally derived collagen medical device, which is designed for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons and cartilage. The company represents a paradigm shift in bone and soft tissue reconstruction. Ortho-ATI is a cell therapy for treatment of chronic tendon injuries. The treatment uses patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound guided injection. The firm has a Good Manufacturing Process (GMP) facility. The facility is licensed by the Therapeutic Goods Administration (TGA) for the manufacture of human tendon cells and cartilage cells for the regeneration of damaged tendon and cartilage.
See Also
What is Orthocell Ltd's EPS (Diluted)?
EPS (Diluted)
-0.1
AUD
Based on the financial report for Dec 31, 2025, Orthocell Ltd's EPS (Diluted) amounts to -0.1 AUD.
What is Orthocell Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-2%
Over the last year, the EPS (Diluted) growth was -150%. The average annual EPS (Diluted) growth rates for Orthocell Ltd have been -8% over the past three years , and -2% over the past ten years .
